Conference Reports for NATAP

Back

DDW - Digestive Disease Week 2015 May 16-19, 2015 Washington DC United States     Effect of Baseline Factors on Response to the Fixed-Dose Combination of Daclatasvir, Asunaprevir, and Beclabuvir, With or Without Ribavirin, in Patients With HCV Genotype 1 Infection and Cirrhosis - (06/29/15)   The Effect of Renal Impairment on Multiple-dose Pharmacokinetics of the Fixed-dose Combination of Daclatasvir/Asunaprevir/Beclabuvir - (06/29/15)   On-treatment HCV RNA as a Predictor of Sustained Virologic Response in HCV Genotype 3-Infected Patients Treated With Daclatasvir and Sofosbuvir: Analysis of the Phase 3 ALLY-3 Study - (06/29/15)   The Natural History of Chronic Hepatitis C. An Updated Look at the Rate of Progression to Cirrhosis and the Incidence of Decompensation in a Large U.S. Health Maintenance Organization - (06/24/15)   The Impact of Sustained Viral Eradication on the Work Productivity of Patients with Chronic Hepatitis C (CHC) from the Five Western European Countries and the United States - (06/16/15)   Cascade of Care for Hepatitis C Virus (HCV) Infection within the U.S. Department of Veterans Affairs (VA) - (06/11/15)   Issues in Hepatitis C: Identification, Access to Care, and Cost - (06/03/15)   The Seroprevalence of Hepatitis C in Immigrants and Refugees from Intermediate and High Endemic Countries: A Systematic Review and Meta-Analysis - (06/03/15)   Predictors of Inpatient Mortality and Resource Utilization of Elderly Patients with Chronic Hepatitis C (CH-C) in the United States - (06/02/15)   A COST-EFFECTIVENESS ANALYSIS OF LDV/SOF+RBV FOR 12 WEEKS VS. LDV/SOF 24 WEEK VS. SOF+SMV 24 WEEKS IN CHC GT1 TE CIRRHOTIC PATIENTS - (06/02/15)   Cost Effectiveness of Hepatitis C Treatment - (05/28/15)   Effectiveness of Sofosbuvir-Based Hepatitis C (HCV) Antiviral Regimens in a Large U.S. Veteran Cohort - (05/28/15)   CANCER RATES IN PATIENTS WITH CHRONIC HEPATITIS C IN A LARGE U.S. HEALTH MAINTENANCE ORGANIZATION - (05/28/15)   The Cost per Cure of Chronic Hepatitis C (HCV). A Cost Mapping Study of Direct Costs Associated With the Treatment of HCV In A Large U.S. Health Maintenance Organization - (05/28/15)   Eradication of Hepatitis C: India as a Model for Resource Limited Settings - (05/28/15)   Effectiveness of Simeprevir-containing Regimens Among Patients With Chronic Hepatitis C Virus in Various US Practice Settings: Interim Analysis of the SONET Study - (05/28/15)   Sustained Virologic Response (SVR) and Liver Disease Progression after Hepatitis C Virus (HCV) treatment initiation: a Real World Analysis using a Large electronic Health record (EHR) Database..... ......SVR reduced progression to cirrhosis or end-stage liver disease by 63-65% - (05/28/15)   Patient and Clinical Characteristics of Chronic Hepatitis C (CHC) Patients Treated With Newer Direct-Acting Antiviral (DAA)-based Regimens From a Large US Payer Perspective - (05/28/15)   Safety and Efficacy of Ledipasvir/Sofosbuvir for the Treatment of Genotype 1 Hepatitis C in Patients Aged 65 Years or Older: A Retrospective Analysis of International Phase 3 Studies - (05/28/15)   Sofosbuvir-Based Regimens for Patients with Hepatitis C Virus Genotype 3 Infection: Summary Results from the VALENCE, BOSON, LONESTAR-2, and ELECTRON-2 Studies - (05/28/15)   Plasma Interferon-γ-Inducible Protein 10 (IP-10) and Response to Interferon-Free Direct-Acting Antiviral Therapy in HCV Genotype 1-Infected Patients With and Without Cirrhosis - Abbvie Analysis - (05/22/15)   High Rates of Adherence to Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir, and Ribavirin in Patients With Cirrhosis: Data From the TURQUOISE-II Study - (05/22/15)   Evaluation of access to care in patients prescribed sofosbuvir-containing regimens; data from the TRIO network - (05/22/15)